
|Videos|November 15, 2022
Updated Analysis of the POSEIDON Trial in mNSCLC from World Lung 2022
Author(s)Edward B. Garon, MD, MS
Dr Garon continues with an explanation of the updated analysis of the POSEIDON trial presented at the 2022 World Conference on Lung Cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















